Key Insights

Highlights

Success Rate

85% trial completion

Published Results

34 trials with published results (24%)

Research Maturity

72 completed trials (51% of total)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 39/100

Termination Rate

9.2%

13 terminated out of 141 trials

Success Rate

84.7%

-1.8% vs benchmark

Late-Stage Pipeline

14%

20 trials in Phase 3/4

Results Transparency

47%

34 of 72 completed with results

Key Signals

34 with results85% success13 terminated

Data Visualizations

Phase Distribution

108Total
Not Applicable (11)
Early P 1 (2)
P 1 (31)
P 2 (44)
P 3 (17)
P 4 (3)

Trial Status

Completed72
Recruiting23
Terminated13
Active Not Recruiting12
Unknown10
Not Yet Recruiting6

Trial Success Rate

84.7%

Benchmark: 86.5%

Based on 72 completed trials

Clinical Trials (141)

Showing 20 of 20 trials
NCT05548062Active Not RecruitingPrimary

Study to Identify and Describe Predictive Factors for Thromboembolic Events in Patients With High-risk Polycythemia Vera

NCT07429266Phase 3RecruitingPrimary

INTREPID: A Study of Sapablursen Evaluating the Safety and Efficacy in Participants With Polycythemia Vera (PV)

NCT06661915Phase 2Suspended

A Randomized Study of ASTX727 With or Without Iadademstat in Advanced Myeloproliferative Neoplasms (MPNs)

NCT02386800Phase 4Active Not Recruiting

CINC424A2X01B Rollover Protocol

NCT02493530Phase 1Completed

TGR-1202 + Ruxolitinib PMF PPV-MF PET-MF MDS/MPN Polycythemia Vera Resistant to Hydroxyurea

NCT05558696Phase 2CompletedPrimary

A Study of Bomedemstat (IMG-7289/MK-3543) in Participants With Polycythemia Vera (IMG-7289-CTP-203/MK-3543-004)

NCT05853458Phase 4TerminatedPrimary

Evaluation of HU-resistance in Adult Patients With Polycythemia Vera Who Meet PV-AIM Predictors

NCT04116502Phase 3RecruitingPrimary

MITHRIDATE: Ruxolitinib Versus Hydroxycarbamide or Interferon as First Line Therapy in High Risk Polycythemia Vera

NCT03878199Phase 1Terminated

Testing the Effect of Taking Ruxolitinib and CPX-351 in Combination for the Treatment of Advanced Phase Myeloproliferative Neoplasms

NCT01384513Phase 2Completed

A Two-Step Approach to Reduced Intensity Bone Marrow Transplant for Patients With Hematological Malignancies

NCT03289910Phase 2Active Not Recruiting

Topotecan Hydrochloride and Carboplatin With or Without Veliparib in Treating Advanced Myeloproliferative Disorders and Acute Myeloid Leukemia or Chronic Myelomonocytic Leukemia

NCT07518940Not ApplicableNot Yet Recruiting

ENERGIA: Personalized Exercise Program for Fatigue in Patients With Myeloproliferative Neoplasms and Chronic Myeloid Leukemia

NCT06351631Phase 3Recruiting

A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017)

NCT06063486Phase 2Recruiting

Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms

NCT06093672Phase 3RecruitingPrimary

Study on Efficacy and Safety of Givinostat Versus Hydroxyurea in Patients With Polycythemia Vera

NCT05198960Phase 3RecruitingPrimary

AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms

NCT04282187Phase 2Recruiting

Decitabine With Ruxolitinib, Fedratinib or Pacritinib for the Treatment of Accelerated/Blast Phase Myeloproliferative Neoplasms

NCT03862157Phase 1Active Not Recruiting

Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

NCT05123365Phase 1Recruiting

An Optimal Dose Finding Study of N-Acetylcysteine in Patients With Myeloproliferative Neoplasms

NCT01199562Active Not Recruiting

Infection Prophylaxis and Management in Treating Cytomegalovirus (CMV) Infection in Patients With Hematologic Malignancies Previously Treated With Donor Stem Cell Transplant

Scroll to load more

Research Network

Activity Timeline